Abstract: Described herein are quaternary ammonium polymers with broad spectrum antimicrobial properties that produce fast acting, long lasting, non-toxic and nonallergenic colorless and transparent durable surface coatings that are resistant to water and common solvents. The surface coatings are easy and cost effective to produce from readily-available materials using versatile synthesis, enabling a wide range of chemical variations. Such coatings are readily applicable to a wide range of surfaces and materials, without leaching of material from the coatings.

Abstract: The present invention relates to a photovoltaic module backsheet comprising, in order: photovoltaic module backsheet comprising a functional layer and a weather-resistant layer, wherein the backsheet is free of fluorinated polymers, characterized in that: i) the functional layer comprises a blend of polyethylene and a polyethylene copolymer, wherein at least 50 wt. % of the functional layer is polyethylene; and ii) the weather-resistant layer comprises, a first sub-layer facing the functional layer and a second sub-layer, wherein a) each of the first sub-layer and the second sub-layer comprise at least 50 wt. % polypropylene; and b) the second sub-layer has a lowest glass transition temperature (Tg) below ?40° C. The present invention also relates to a process for producing the backsheet and a photovoltaic module comprising the backsheet according to the present invention.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: The present invention relates to a method for casting building material to form a construction element using a computer-controlled apparatus. The method comprises the steps of: moving the material deposition head and selectively depositing material, to fabricate a formwork; pouring building material in contact with at least a portion of the formwork; at least partially curing the building material, thereby forming the construction element; and removing at least a portion of the formwork from the construction element.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: The present invention relates to a photovoltaic module backsheet, comprising photovoltaic module backsheet comprising, in order: a functional layer; a connecting layer; and a weather-resistant layer, wherein each layer of the backsheet comprises at least 50 wt. % polyolefin and the backsheet is free of fluorinated polymers, characterized in that: i) the functional layer comprises a blend of polyethylene and a polyethylene copolymer; and ii) the weather-resistant layer comprises polypropylene; a UV stabilizer; a primary antioxidant, which primary antioxidant is a phenolic antioxidant or an aromatic amine antioxidant; and secondary antioxidant, which secondary antioxidant is a trivalent phosphorus containing antioxidant or a thioether containing antioxidant. The present invention also relates to a process for producing the backsheet and a photovoltaic module comprising the backsheet according to the present invention.

Abstract: The present invention relates to a backsheet for photovoltaic modules comprising a polymeric layer comprising an aliphatic polyamide comprising 1,10-decanedioic acid. Examples of such aliphatic polyamides are polyamide 4,10, polyamide 5,10 or polyamide 6,10. Preferably polyamide 4,10 is present in the rear layer of the backsheet. A polyolefin layer is preferably present in the core layer of the backsheet. It is however also possible that the polyamide is present in the core layer and polyolefin is present in the rear layer of the backsheet. The polyolefin is preferably chosen from the group consisting of polyethylene, polypropylene or ethylene-propylene copolymers. More preferably the polyolefin is polypropylene. The backsheet preferably comprises at least a further polymeric layer comprising a polymer selected from the group consisting of an optionally functionalized polyolefin such as a maleic anhydride functionalized polypropylene homo or copolymer.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: The present invention relates to a method for casting building material to form a construction element using a computer-controlled apparatus. The method comprises the steps of: moving the material deposition head and selectively depositing material, to fabricate a formwork; pouring building material in contact with at least a portion of the formwork; at least partially curing the building material, thereby forming the construction element; and removing at least a portion of the formwork from the construction element.

Abstract: The present invention relates to a method for casting building material to form a construction element using a computer-controlled apparatus. The method comprises the steps of: moving the material deposition head and selectively depositing material, to fabricate a formwork; pouring building material in contact with at least a portion of the formwork; at least partially curing the building material, thereby forming the construction element; and removing at least a portion of the formwork from the construction element.

Abstract: The present invention relates to an electro-conductive back-sheet for back-contact photovoltaic cell technologies comprising an aluminum layer, a cold sprayed metal layer on top of the aluminum layer and a polymeric back-sheet having an (OTR) of at least 20 cm3/m2·atm per day. The metal used for the metal layer is chosen from the group consisting of copper, tin, silver or nickel, or mixtures of two or more thereof or alloys of two or more thereof. Preferably the metal is copper. The metal layer preferably has a thickness in the range of 50 nm-10 ?m. The present invention further relates to process for the manufacturing of the electro-conductive back-sheet. The present invention also relates to a photovoltaic module comprising the electro-conductive back-sheet.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.

Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.